Title:
TREATMENT CANCERS USING COMBINATION COMPRISING PARP INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2018/059437
Kind Code:
A1
Abstract:
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a chemotherapeutic agent and the use thereof.
Inventors:
WANG LAI (CN)
TANG ZHIYU (CN)
LUO LUSONG (CN)
WEI MIN (CN)
LI KANG (CN)
SONG JING (CN)
ZHANG TONG (CN)
WANG HEXIANG (CN)
REN BO (CN)
ZHOU CHANGYOU (US)
TANG ZHIYU (CN)
LUO LUSONG (CN)
WEI MIN (CN)
LI KANG (CN)
SONG JING (CN)
ZHANG TONG (CN)
WANG HEXIANG (CN)
REN BO (CN)
ZHOU CHANGYOU (US)
Application Number:
PCT/CN2017/103660
Publication Date:
April 05, 2018
Filing Date:
September 27, 2017
Export Citation:
Assignee:
BEIGENE LTD (KY)
WANG LAI (CN)
WANG LAI (CN)
International Classes:
A61K31/551; A61P35/00; C07D471/16; C07D471/22; C07D487/06; C07K16/28
Domestic Patent References:
| WO2013097225A1 | 2013-07-04 | |||
| WO2015035606A1 | 2015-03-19 | |||
| WO2016000619A1 | 2016-01-07 | |||
| WO2013097225A1 | 2013-07-04 | |||
| WO2015035606A1 | 2015-03-19 |
Foreign References:
| US20160222012A1 | 2016-08-04 | |||
| CN2016096200W | 2016-08-22 |
Other References:
HANAHAN DWEINBERG R A: "Hallmarks of cancer: the next generation", CELL, vol. 144, no. 5, 2011, pages 646 - 74, XP028185429, DOI: 10.1016/j.cell.2011.02.013
LI XHEYER W D: "Homologous recombination in DNA repair and DNA damage tolerance", CELL RES, vol. 18, no. 1, 2008, pages 99 - 113
ROULEAU MPATEL AHENDZEL M J ET AL.: "PARP inhibition: PARP1 and beyond", NAT REV CANCER, vol. 10, no. 4, 2010, pages 293 - 301, XP008165440, DOI: 10.1038/nrc2812
BRYANT H ESCHULTZ NTHOMAS H D ET AL.: "Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase", NATURE, vol. 434, no. 7035, 2005, pages 913 - 7, XP007906257, DOI: 10.1038/nature03443
FARMER HMCCABE NLORD C J ET AL.: "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy", NATURE, vol. 434, no. 7035, 2005, pages 917 - 21, XP002516395, DOI: 10.1038/nature03445
LI XHEYER W D: "Homologous recombination in DNA repair and DNA damage tolerance", CELL RES, vol. 18, no. 1, 2008, pages 99 - 113
ROULEAU MPATEL AHENDZEL M J ET AL.: "PARP inhibition: PARP1 and beyond", NAT REV CANCER, vol. 10, no. 4, 2010, pages 293 - 301, XP008165440, DOI: 10.1038/nrc2812
BRYANT H ESCHULTZ NTHOMAS H D ET AL.: "Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase", NATURE, vol. 434, no. 7035, 2005, pages 913 - 7, XP007906257, DOI: 10.1038/nature03443
FARMER HMCCABE NLORD C J ET AL.: "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy", NATURE, vol. 434, no. 7035, 2005, pages 917 - 21, XP002516395, DOI: 10.1038/nature03445
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: